Tokyo, Jan. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060320) titled 'Verification of the effect of honey intake on improving cough sensitivity in humans' on Jan. 15.

Study Type: Interventional

Study Design: Basic Design - Cross-over Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Shiba Palace Clinic

Condition: Condition - Healthy adults Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To verify the effect of honey intake on improving cough sensitivity Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - To intake honey single time Interventions/Control_2 - To intake placebo single time

Eligibility: Age-lower limit - 20 years-old = Gender - Male and Female Key inclusion criteria - 1) Japanese males and females aged 20 to 64 years old at the time of informed consent 2) Healthy adults 3) Subjects who are concerned about coughing or throat discomfort 4) Subjects who regularly eat three meals a day 5) Subjects who Subjects who can perform informed consent 6) Subjects who can understand and comply with the management instructions during the study period Key exclusion criteria - 1) Subjects who regularly consume honey 2) Subjects unable to maintain a regular daily routine 3) Pregnant, intending to become pregnant, or breastfeeding 4) Subjects participating in other clinical tests or studies during the test period 5) Subjects who are supposed not to be proper by the investigator 6) Subjects planning medication treatment for hay fever during the test period 7) Subjects unable to discontinue medications that may affect test results (e.g., cough suppressants, cold remedies, allergy suppressants) 7 days prior to the test 8) Subjects at risk of allergic reactions to test components (honey, chili pepper extract) 9) Subjects planning to change their diet during the test period 10) Subjects with cardiovascular or respiratory diseases, asthma, severe allergic diseases, liver dysfunction, kidney or heart disease, organ dysfunction, diabetes, or other serious illnesses 11) Subjects with a history of major gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.) 12) Subjects who consume excessive amounts of alcohol (equivalent to 20g of pure alcohol or more per day) 13) Smokers (or individuals living with smokers) 14) Subjects experiencing hay fever symptoms during the test period Target Size - 100

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 12 Month 24 Day Date of IRB - 2025 Year 12 Month 25 Day Anticipated trial start date - 2026 Year 02 Month 15 Day Last follow-up date - 2026 Year 04 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068958

Disclaimer: Curated by HT Syndication.